Sandoz Biosimilar Clears FDA Panel In Milestone Vote
An independent panel on Wednesday unanimously advised the U.S. Food and Drug Administration to approve Sandoz Inc.'s copycat version of Amgen Inc.'s Neupogen, a landmark win for the first product to...To view the full article, register now.
Already a subscriber? Click here to view full article